2021 Update on Metastatic Triple Negative Breast Cancer Treatment
Treatment options for triple negative breast cancer are increasing. Learn about what’s available now and what’s being studied in clinical trials.
Screening for Breast Cancer Brain Metastases
Current guidelines about screening for brain mets are being questioned. Read about the pros and cons of BCBM screening.
Participating in a Trial: Patient Voices
Read powerful stories from patients who have enrolled in one–or several–clinical trials.
FDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®) in combination with chemotherapy, for treating metastatic HER2-positive breast cancer.
Treating Breast Cancer Brain Mets
Read further for an overview of current research and new therapies for breast cancer brain metastasis (BCBM).
What You Need to Know About Washout Periods
A washout period describes the length of time that someone enrolled in a trial must not receive any treatment before receiving the trial’s experimental treatment. Click to learn about why washout periods are required, as well as concerns and potential solutions.
What is Next-Generation Sequencing?
Next-generation sequencing (NGS) is when all of the genes in a tumor are tested for genomic mutations. Read the discussions about whether NGS improves survival and quality of life, and the ESMO recommendations regarding NSG for patients with metastatic cancers (including breast).
Lines of Therapy: New Drugs May Change MBC Treatment
Which therapy to use for the first, second or third line of treatment for metastatic breast cancer is now under rigorous research as more new therapies are available for treating MBC.
What Are Lines of Therapy and What You Need to Know
“Lines of therapy” describes the order in which therapies are given as MBC progresses. Learn how lines of therapy are chosen and about current MBC treatment guidelines.